Menu
Search
|

Menu

Close
X

Oxford Immunotec Global PLC OXFD.OQ (NASDAQ Stock Exchange Global Market)

13.95 USD
+0.20 (+1.45%)
As of 12:16 PM EDT
Previous Close 13.75
Open 13.74
Volume 8,265
3m Avg Volume 78,159
Today’s High 14.02
Today’s Low 13.74
52 Week High 19.10
52 Week Low 12.15
Shares Outstanding (mil) 25.51
Market Capitalization (mil) 427.87
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
34
FY18
60
FY17
75
FY16
86
EPS (USD)
FY19
-0.034
FY18
0.387
FY17
-0.736
FY16
-1.000
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
4.39
7.91
Price to Book (MRQ)
vs sector
7.35
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
56.70
14.55
LT Debt to Equity (MRQ)
vs sector
56.53
10.20
Return on Investment (TTM)
vs sector
-39.14
14.48
Return on Equity (TTM)
vs sector
-50.71
15.78

EXECUTIVE LEADERSHIP

Richard Sandberg
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Peter Wrighton-Smith
Chief Executive Officer, Director, Since 2002
Salary: $382,107.00
Bonus: --
Matthew McLaughlin
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Stefan Linn
Chief Operating Officer, Since 2017
Salary: $400,000.00
Bonus: --
Ronald Andrews
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

94C Innovation Drive
ABINGDON     OX14 4RZ

Phone: +441235.442780

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

SPONSORED STORIES